Kenneth Emancipator

16.6k total citations · 3 hit papers
73 papers, 4.6k citations indexed

About

Kenneth Emancipator is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Immunology. According to data from OpenAlex, Kenneth Emancipator has authored 73 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 11 papers in Immunology. Recurrent topics in Kenneth Emancipator's work include Cancer Immunotherapy and Biomarkers (52 papers), Lung Cancer Treatments and Mutations (16 papers) and Cancer Genomics and Diagnostics (11 papers). Kenneth Emancipator is often cited by papers focused on Cancer Immunotherapy and Biomarkers (52 papers), Lung Cancer Treatments and Mutations (16 papers) and Cancer Genomics and Diagnostics (11 papers). Kenneth Emancipator collaborates with scholars based in United States, South Korea and Canada. Kenneth Emancipator's co-authors include Jared Lunceford, Marisa Dolled‐Filhart, Jonathan Juco, Yung‐Jue Bang, Joseph P. Eder, Kumudu Pathiraja, Shilpa Gupta, Minori Koshiji, Martin H. Kroll and Barbara Burtness and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Kenneth Emancipator

72 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

2016 848 citations Kei Muro, Hyun Cheol Chung et al. The Lancet Oncology profile →
T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028

2018 656 citations Patrick A. Ott, Yung‐Jue Bang et al. Journal of Clinical Oncology profile →
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer

2018 378 citations Karina Kulangara, Nancy R. Zhang et al. Archives of Pathology & Laboratory Medicine profile →

Peers

Kenneth Emancipator

ONCOL

PRM

IMMUN

SURGE

Suguru Hasegawa Japan

Masaji Tani Japan

David M. Ota United States

Nirag Jhala United States

Marcella M. Johnson United States

Jy‐Ming Chiang Taiwan

S. Meijer Netherlands

Hyojin Kim South Korea

Werner Hohenberger Germany

Matthew F. Kalady United States

Suguru Hasegawa Japan

Kenneth Emancipator

2.3k ×0.7

ONCOL

962 ×0.5

PRM

401 ×0.3

IMMUN

1.8k ×1.8

SURGE

423 ×0.8

Citations per year, relative to Kenneth Emancipator Kenneth Emancipator (= 1×) peers Suguru Hasegawa

Countries citing papers authored by Kenneth Emancipator

Since Specialization

Citations

This map shows the geographic impact of Kenneth Emancipator's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenneth Emancipator with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenneth Emancipator more than expected).

Fields of papers citing papers by Kenneth Emancipator

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenneth Emancipator. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenneth Emancipator. The network helps show where Kenneth Emancipator may publish in the future.

Co-authorship network of co-authors of Kenneth Emancipator

This figure shows the co-authorship network connecting the top 25 collaborators of Kenneth Emancipator. A scholar is included among the top collaborators of Kenneth Emancipator based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kenneth Emancipator. Kenneth Emancipator is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Polewski, Monika D., Malinka Jansson, Kenneth Emancipator, et al.. (2021). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Head and Neck Squamous Cell Carcinoma. 5(1). 9–17. 2 indexed citations

Emancipator, Kenneth, Lingkang Huang, Deepti Aurora-Garg, et al.. (2020). Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer. Modern Pathology. 34(3). 532–541. 71 indexed citations

Emancipator, Kenneth. (2020). Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker. The AAPS Journal. 23(1). 5–5. 21 indexed citations

Ott, Patrick A., Yung‐Jue Bang, Sarina A. Piha‐Paul, et al.. (2018). T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. Journal of Clinical Oncology. 37(4). 318–327. 656 indexed citations breakdown →

Kulangara, Karina, Nancy R. Zhang, Ellie Corigliano, et al.. (2018). Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer. Archives of Pathology & Laboratory Medicine. 143(3). 330–337. 378 indexed citations breakdown →

Ott, Patrick A., Y-J. Bang, A.R. Abdul Razak, et al.. (2017). Relationship of PD-L1 and a T-cell inflamed gene expression profile (GEP) to clinical response in a multicohort trial of solid tumors (KEYNOTE [KN]028). Annals of Oncology. 28. v22–v22. 5 indexed citations

Cho, Jong Ho, Yoon‐La Choi, Yu Feng, et al.. (2017). Programmed Death Ligand 1 Expression in Paired Non–Small Cell Lung Cancer Tumor Samples. Clinical Lung Cancer. 18(6). e473–e479. 32 indexed citations

Cho, Jong Ho, Wei Zhou, Yoon‐La Choi, et al.. (2017). Retrospective Molecular Epidemiology Study of PD-L1 Expression in Patients with EGFR-Mutant Non-small Cell Lung Cancer. Cancer Research and Treatment. 50(1). 95–102. 26 indexed citations

Ott, Patrick A., Sarina A. Piha‐Paul, Pamela N. Münster, et al.. (2017). Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal. Annals of Oncology. 28(5). 1036–1041. 164 indexed citations

10.

Hui, Rina, Edward B. Garon, Natasha B. Leighl, et al.. (2017). Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. Annals of Oncology. 28(4). 874–881. 188 indexed citations

11.

Roach, Charlotte, Nancy R. Zhang, Ellie Corigliano, et al.. (2016). Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non–Small-cell Lung Cancer. Applied immunohistochemistry & molecular morphology. 24(6). 392–397. 249 indexed citations

12.

Muro, Kei, Hyun Cheol Chung, Veena Shankaran, et al.. (2016). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The Lancet Oncology. 17(6). 717–726. 848 indexed citations breakdown →

13.

Sun, Jong‐Mu, Wei Zhou, Yoon‐La Choi, et al.. (2016). Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases. Journal of Thoracic Oncology. 11(7). 1003–1011. 129 indexed citations

14.

Dolled‐Filhart, Marisa, Darren Locke, Jennifer H. Yearley, et al.. (2016). Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue. Archives of Pathology & Laboratory Medicine. 140(11). 1259–1266. 56 indexed citations

15.

Dolled‐Filhart, Marisa, Charlotte Roach, Grant Toland, et al.. (2016). Development of a Companion Diagnostic for Pembrolizumab in Non–Small Cell Lung Cancer Using Immunohistochemistry for Programmed Death Ligand-1. Archives of Pathology & Laboratory Medicine. 140(11). 1243–1249. 86 indexed citations

16.

Cho, Jungwan, Wei Zhou, Yoon‐La Choi, et al.. (2015). 26O Molecular epidemiology study of PD-L1 expression in patients (pts) with EGFR-mutant NSCLC. Annals of Oncology. 26. ix8–ix8. 1 indexed citations

17.

Garon, Edward B., Leena Gandhi, Naiyer A. Rizvi, et al.. (2014). Antitumor Activity of Pembrolizumab (Pembro; Mk-3475) and Correlation with Programmed Death Ligand 1 (Pd-L1) Expression in a Pooled Analysis of Patients (Pts) with Advanced Non–Small Cell Lung Carcinoma (Nsclc). Annals of Oncology. 25. v1–v1. 53 indexed citations

18.

Emancipator, Kenneth. (1999). Laboratory Diagnosis and Monitoring of Diabetes Mellitus. American Journal of Clinical Pathology. 112(5). 665–674. 79 indexed citations

19.

Emancipator, Kenneth, Ronald J. Elin, & Thomas A. Fleisher. (1992). Comparison of two automated nephelometers. Journal of Clinical Laboratory Analysis. 6(6). 399–404. 6 indexed citations

20.

Emancipator, Kenneth, Evan M. Cadoff, & M. Desmond Burke. (1988). Analytical versus clinical sensitivity and specificity in pregnancy testing. American Journal of Obstetrics and Gynecology. 158(3). 613–616. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact